Skip to main content
letter
. 2022 Aug 29;140(26):2849–2852. doi: 10.1182/blood.2022016757

Figure 1.

Figure 1.

Cumulative incidence of developing (A) any hematologic disease, (B) immune thrombocytopenia, and (C) hematologic neoplasia over up to 32 years of follow-up. Black hash symbols are censored events due to death or loss to follow-up. The 5-, 15-, and 25-year cumulative incidences with 95% confidence intervals for the persistent isolated mild thrombocytopenia group are additionally given.